1. Home
  2. INAB vs UTSI Comparison

INAB vs UTSI Comparison

Compare INAB & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INAB
  • UTSI
  • Stock Information
  • Founded
  • INAB 2016
  • UTSI 1991
  • Country
  • INAB United States
  • UTSI China
  • Employees
  • INAB N/A
  • UTSI N/A
  • Industry
  • INAB Biotechnology: Pharmaceutical Preparations
  • UTSI Telecommunications Equipment
  • Sector
  • INAB Health Care
  • UTSI Telecommunications
  • Exchange
  • INAB Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • INAB 23.5M
  • UTSI 25.4M
  • IPO Year
  • INAB 2021
  • UTSI 2000
  • Fundamental
  • Price
  • INAB $0.36
  • UTSI $2.63
  • Analyst Decision
  • INAB Strong Buy
  • UTSI
  • Analyst Count
  • INAB 3
  • UTSI 0
  • Target Price
  • INAB $7.75
  • UTSI N/A
  • AVG Volume (30 Days)
  • INAB 2.7M
  • UTSI 4.5K
  • Earning Date
  • INAB 11-12-2024
  • UTSI 09-05-2024
  • Dividend Yield
  • INAB N/A
  • UTSI N/A
  • EPS Growth
  • INAB N/A
  • UTSI N/A
  • EPS
  • INAB N/A
  • UTSI N/A
  • Revenue
  • INAB N/A
  • UTSI $14,958,000.00
  • Revenue This Year
  • INAB N/A
  • UTSI N/A
  • Revenue Next Year
  • INAB N/A
  • UTSI N/A
  • P/E Ratio
  • INAB N/A
  • UTSI N/A
  • Revenue Growth
  • INAB N/A
  • UTSI 14.41
  • 52 Week Low
  • INAB $0.22
  • UTSI $2.20
  • 52 Week High
  • INAB $2.48
  • UTSI $3.70
  • Technical
  • Relative Strength Index (RSI)
  • INAB 50.42
  • UTSI 41.97
  • Support Level
  • INAB $0.31
  • UTSI $2.50
  • Resistance Level
  • INAB $0.37
  • UTSI $2.89
  • Average True Range (ATR)
  • INAB 0.04
  • UTSI 0.14
  • MACD
  • INAB 0.01
  • UTSI -0.03
  • Stochastic Oscillator
  • INAB 38.51
  • UTSI 21.42

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp operates as a telecom infrastructure provider. It develops technology for bandwidth from cloud-based services, mobile, streaming, and other applications. The range of solutions is designed to expand and modernize telecommunications networks through smooth network system integration, lower operating costs, and increased broadband access. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. The company operates in China, India, Japan, Taiwan and other countries.

Share on Social Networks: